Mount Sinai Logo

Philip Friedlander

  • ASSISTANT PROFESSOR Medicine, Hematology and Medical Oncology
  • ASSISTANT PROFESSOR Dermatology
Print ProfilePrint Profile

Certifications

  • Medical Oncology

Education

  • MD, Columbia University

  • Internship, Internal Medicine
    Columbia-Presbyterian Medical Center

  • Residency, Internal Medicine
    Columbia-Presbyterian Medical Center

  • Fellowship, Oncology
    Memorial Sloan-Kettering Cancer Center

Biography

    Dr. Friedlander received medical school training at Columbia University where he obtained his M.D. and Ph.D. degree in  Biology. He remained at Columbia Presbyterian Medical Center to complete his postdoctoral training in Internal Medicine and subsequently completed a clinical fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center. He then joined the faculty of the Dana Farber Cancer Institute/Brigham and Women’s Hospital as an attending physician within the Melanoma and Cutaneous Oncology Programs and as an Instructor of Medicine at Harvard Medical School.  His clinical interests include the development of targeted therapies and immunotherapies for patients with melanoma, merkel cell carcinoma, advanced cutaneous squamous cell carcinoma, basal cell carcinoma, and sebaceous gland tumors.  At the Dana Farber Cancer Institute he acted as a principal investigator testing novel therapeutic approaches for melanoma including PARP inhibition, hsp90 inhibition, anti-apoptotic approaches, and immune modulatory and anti-CTLA4 based strategies. He investigated in non-melanoma skin cancers novel therapeutic strategies such as hedgehog signaling pathway inhibition in advanced basal cell carcinoma.  As a member of the Division of Hematology/Medical Oncology and as the Director of the Melanoma Medical Oncology Program at Mount Sinai, he will be caring for patients with cutaneous malignancies and continue working to develop collaborative translational and basic science  projects  and treatments for patients with cutaneous malignancies.  

    In the News:

    Watch Dr. Friedlander discuss a new FDA approved treatment (Erivedge) for Basal Cell Carcinoma:
    KTVX-TV (ABC/Salt Lake City, Utah) 
    KRNV-TV (NBC/Reno, Nevada)
    WNAV-AM (Baltimore, Maryland)
     

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Friedlander during 2013 and/or 2014. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting:

  • Bristol-Myers Squibb

Scientific Advisory Board:

  • Genentech, Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

Icahn Medical Institute Room Tisch Cancer Inst.
1425 Madison Avenue
New York, NY 10029


Address

Hess CSM Building Floor Hess Tower
1470 Madison Avenue
New York, NY 10029

Tel: 212-824-8584
Ruttenberg Treatment Center

1470 Madison Avenue
3rd floor
New York, NY 10029

Tel: 212-241-6756
Get Directions